Results 291 to 300 of about 53,729,253 (423)

Role of Nanomedicine in Transforming Pharmacotherapy for Substance Use Disorder (SUD). [PDF]

Wiley Interdiscip Rev Nanomed Nanobiotechnol
Patne AY, Mohapatra S, Mohapatra SS.
europepmc   +1 more source

The conception of the ABCD study: From substance use to a broad NIH collaboration

Developmental Cognitive Neuroscience, 2017
N. Volkow, G. Koob, R. Croyle, D. Bianchi, J. Gordon, W. Koroshetz, E. Perez-stable, W. Riley, M. Bloch, K. Conway, B. Deeds, G. Dowling, S. Grant, K. Howlett, J. Matochik, Glen D. Morgan, M. Murray, A. Noronha, C. Spong, Eric M. Wargo, K. Warren, S. Weiss   +21 more
semanticscholar   +1 more source

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

Mental health challenges and substance use in student-athletes: prevalence and impact. [PDF]

Front Sports Act Living
Moore EM, Simmons MA, Threatt J.
europepmc   +1 more source

Studies on Active Substances in Herbs Used for Hair Treatment. I. Effects of Herb Extracts on Hair Growth and Isolation of an Active Substance from Polyporus umbellatus F.

, 1994
Yasunori INAOKA, Akemi SHAKUYA, H Fukazawa, Hitoshi Ishida, Haruo Nukaya, Kuniro Tsuji, Hideo KURODA, Masanori Okada, Makoto Fukushima, Takuo Kosuge   +9 more
openalex   +2 more sources

Sex and gender differences in substance use disorders.

Clinical Psychology Review, 2017
R. K. McHugh, V. Votaw, Dawn E. Sugarman, Shelly F. Greenfield   +3 more
semanticscholar   +1 more source

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

Molecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen, Chung‐Teng Wang, Jia‐Ming Chang, Ai‐Li Shiau, Gia‐Shing Shieh, Yau‐Lin Tseng, Yi‐Ting Yen, Tang‐Hsiu Huang, Li‐Hsin Cheng, Yu‐Chih Wu, Chao‐Liang Wu, Bing‐Hua Su, Pensee Wu   +12 more
wiley   +1 more source

Exploring spatial dynamics of trauma and substance use among suicide deaths in the United States (2017-2021). [PDF]

Inj Epidemiol
Smith BD, Cadet K, Powell TW.
europepmc   +1 more source

βA425–35 modulates substance P effect on rat skin microvasculature in aged rats: pharmacological manipulation using SEC-receptor ligands

, 1994
Zeinab G. Khalil, Katarina Sanderson, Pernilla Isberg, Maryam Bassirat, Bruce G. Livett, Robert D. Helme   +5 more
openalex   +1 more source

Determination of ADP/ATP translocase isoform ratios in malignancy and cellular senescence

Molecular Oncology, EarlyView.
The individual functions of three isoforms exchanging ADP and ATP (ADP/ATP translocases; ANTs) on the mitochondrial membrane remain unclear. We developed a method for quantitatively differentiating highly similar human ANT1, ANT2, and ANT3 using parallel reaction monitoring. This method allowed us to assess changes in translocase levels during cellular
Zuzana Liblova, Dominika Maurencova, Barbora Salovska, Marek Kratky, Tomas Mracek, Zuzana Korandova, Alena Pecinova, Pavla Vasicova, David Rysanek, Ladislav Andera, Ivo Fabrik, Rudolf Kupcik, Pavel Kashmel, Pinky Sultana, Vojtech Tambor, Jiri Bartek, Josef Novak, Marie Vajrychova, Zdenek Hodny   +18 more
wiley   +1 more source